📊 QNRX Key Takeaways
Is Quoin Pharmaceuticals, Ltd. (QNRX) a Good Investment?
Quoin Pharmaceuticals is a pre-revenue biotech company with acute financial distress, burning $4.9M in operating cash annually against only $3.1M in cash reserves, resulting in approximately 6-7 months of runway. The company exhibits severe fundamental weakness with negative operating income of -$15.8M, negative ROE of -57% and ROA of -31.8%, with no visible revenue generation or path to near-term profitability, creating existential solvency risk.
Quoin Pharmaceuticals, Ltd. Key Strengths (QNRX)
- Strong liquidity position with current ratio of 2.87x and quick ratio of 2.87x provides near-term operational flexibility
- Zero debt burden (Debt/Equity ratio of 0.00x) minimizes financial leverage risk and avoids debt servicing pressure
- Positive stockholders equity of $8.8M maintains solvency status despite operational losses
QNRX Stock Risks: Quoin Pharmaceuticals, Ltd. Investment Risks
- Pre-revenue status with no sales generation creates dependency on capital infusions for survival
- Critical cash runway of approximately 6-7 months at current burn rate threatens continued operations without financing
- Persistent operating losses of -$15.8M with negative returns on equity (-57%) and assets (-31.8%) indicate rapid shareholder value destruction
- Operating cash flow of -$4.9M demonstrates cash burn exceeds revenue generation by significant margin
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway until insolvency
- Pipeline milestone achievements and clinical trial progress toward revenue generation
- Management's capital raising activities and dilution impact on equity holders
Quoin Pharmaceuticals, Ltd. (QNRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.87x current ratio provides a solid financial cushion.
QNRX Profit Margin, ROE & Profitability Analysis
QNRX vs Healthcare Sector: How Quoin Pharmaceuticals, Ltd. Compares
How Quoin Pharmaceuticals, Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Quoin Pharmaceuticals, Ltd. Stock Overvalued? QNRX Valuation Analysis 2026
Based on fundamental analysis, Quoin Pharmaceuticals, Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Quoin Pharmaceuticals, Ltd. Balance Sheet: QNRX Debt, Cash & Liquidity
QNRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Quoin Pharmaceuticals, Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
QNRX Revenue Growth, EPS Growth & YoY Performance
Quoin Pharmaceuticals, Ltd. Dividends, Buybacks & Capital Allocation
QNRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Quoin Pharmaceuticals, Ltd. (CIK: 0001671502)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QNRX
What is the AI rating for QNRX?
Quoin Pharmaceuticals, Ltd. (QNRX) has an AI grade of D with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QNRX's key strengths?
Claude: Strong liquidity position with current ratio of 2.87x and quick ratio of 2.87x provides near-term operational flexibility. Zero debt burden (Debt/Equity ratio of 0.00x) minimizes financial leverage risk and avoids debt servicing pressure.
What are the risks of investing in QNRX?
Claude: Pre-revenue status with no sales generation creates dependency on capital infusions for survival. Critical cash runway of approximately 6-7 months at current burn rate threatens continued operations without financing.
What is QNRX's revenue and growth?
Quoin Pharmaceuticals, Ltd. reported revenue of N/A.
Does QNRX pay dividends?
Quoin Pharmaceuticals, Ltd. does not currently pay dividends.
Where can I find QNRX SEC filings?
Official SEC filings for Quoin Pharmaceuticals, Ltd. (CIK: 0001671502) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QNRX's EPS?
Quoin Pharmaceuticals, Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is QNRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Quoin Pharmaceuticals, Ltd. has a D grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is QNRX stock overvalued or undervalued?
Valuation metrics for QNRX: ROE of -57.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is QNRX's AI grade for 2026?
Our dual AI analysis gives Quoin Pharmaceuticals, Ltd. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QNRX's free cash flow?
Quoin Pharmaceuticals, Ltd.'s operating cash flow is $-4.9M, with capital expenditures of N/A.
How does QNRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -57.0% (avg: 15%), current ratio 2.87 (avg: 2).